BioNTech pledges major UK investment
BioNTech’s commitment aligns with the UK Government’s Plan for Change, which involves accelerating growth of the pharmaceutical industry.
List view / Grid view
BioNTech’s commitment aligns with the UK Government’s Plan for Change, which involves accelerating growth of the pharmaceutical industry.
The MHRA’s consultation, announced on International Clinical Trials Day, is intended to support creation of innovative UK trials.
The announcement supports the UK Government’s broader plans for reformation of longer-term funding for the research and development sector.
This exclusive report addresses the key challenges and breakthroughs shaping the future of cell and gene therapy, from QC and analytical development to advanced manufacturing strategies. Discover practical solutions you can implement to drive progress for your organisation.
Current market conditions in the pharmaceutical industry have driven the change to its executive leadership team, according to Novo Nordisk.
This article offers key industry perspectives on the UK government’s recent immigration whitepaper and highlights the challenge of balancing economic growth and attracting skilled talent.
The unique mechanism of action of efimosfermin supports its potential as a new standard-of-care in liver disease.
12 May 2025 | By Mettler Toledo
This virtual panel explores impurity control in pharmaceutical waters, the differences between microbial and organic contaminants, and best practices for measurement and treatment.
The novel cell therapy utilises a shortened manufacturing process compared to standard production timelines, offering potential for enhanced therapeutic capability.
Medicines for Europe calls for continued progress of pharmaceutical reforms such as the Critical Medicines Act, to support production of essential medicines in the region.
In this article, Dave Elder reviews the European Medicines Agency (EMA)’s updated reflection paper on the qualification of non-mutagenic impurities (NMIs), which outlines alternative approaches to animal testing.
The multi-billion-pound deal provides a boost to the UK’s economy, however it lacks provision to aid the country’s growth ambitions, states the ABPI.
Despite its potential to become a more attractive destination for drug developers, new research insists the EU market makes improvements such as faster regulatory approvals and closer collaboration.
The biologic delivered sustained remission in adults with the inflammatory bowel disease (IBD) over the two-year study, results show.
With clinical data showing the gene therapy can address large and challenging chronic wounds, the FDA’s decision will help improve quality of life for dystrophic epidermolysis bullosa (DEB) patients.